Corticotropin-releasing hormone (CRH) plays major roles in coordination of the stress response and regulation of the immune/inflammatory reaction, two important functions associated with sexual dimorphism. Two overlapping segments of the 5' flanking region of the human (h) CRH gene, the proximal 0.9 kb (containing two perfect half-palindromic estrogenresponsive elements IEREsI) and the 2.4 kb (including the former and containing two additional perfect half-palindromic EREs), were examined for their ability to confer estrogen-mediated transcriptional enhancement to a homologous or heterologous promoter. The level of estrogen-induced transactivation by the 0.9-and 2.4-kb segments was determined by chloramphenicol acetyltransferase analysis in CV-1 cells cotransfected with estrogen receptor (ER) cDNA expression plasmids, and found to be respectively -10% and 20% of that of the strongly estrogen-responsive Xenopus vitellogenin A2 enhancer. Gel retardation and immunoprecipitation demonstrated specific association between the perfect half-palindromic EREs of hCRH gene and the DNA binding domain of hER in vitro. These findings may constitute the basis of sexual dimorphism in the expression of the CRH gene in the central nervous system and periphery, and might shed light in existing gender differences in stress response and immune regulation. (J. Clin. Invest.
Introduction
Corticotropin-releasing hormone (CRH),' a 41-amino acid peptide, plays a pivotal role in the coordination of the stress response and the regulation ofthe immune/ inflammatory reaction ( 1-7). In the central nervous system (CNS), CRH modu-lates the synthesis and release of adrenocorticotropic hormone (ACTH) and mediates, together with norepinephrine, many hormonal, autonomic, behavioral, and immunological effects ofstress (8) (9) (10) (11) (12) (13) . CNS CRH, thus, inhibits the reproductive and growth axes, stimulates the sympathetic system, causes enhanced arousal, and suppresses the immune system, the latter indirectly, through activation of the hypothalamic-pituitaryadrenal (HPA) axis and the sympathetic system (3, 4, 7, 14, 15) . Interestingly, CRH, designated immune CRH, is also secreted peripherally, in inflammatory sites, where it exerts direct proinflammatory actions (16, 17) . The immune/inflammatory reaction appears, thus, as the outcome of two antithetical actions of CRH, one central, endocrine, which is inhibitory, and the other peripheral, auto/paracrine, which is stimulatory.
Sex differences in the regulation of the stress response, in general, and the HPA axis, in particular, as well as sexual dimorphism of the immune/inflammatory reaction, including susceptibility to autoimmune disease, have been described in various species, including the mouse, rat, and human (18) (19) (20) (21) (22) . These studies have suggested that gonadal steroids interact in a regulatory manner with CNS and peripheral substrates of the stress response, including the HPA axis, and the immune/ inflammatory reaction. Estrogens and androgens have been implicated in these differences, however, whether their effects are direct or via estrogen-or androgen-dependent mediators is unclear. The exact site(s) ofthis interaction and its mechanism(s) is (are) not well understood, but the central role that CRH plays in these functions suggests that this hormone may be a common key point of such regulation.
To examine the potential sex steroid regulation of the human (h)CRH gene, we cloned and sequenced 3.7 kb of its 5' flanking region (23; N. C. Vamvakopoulos and G. P. Chrousos, unpublished data; and Gene Bank Accession No. X 67661 ) and performed a computer search for the presence of consensus regulatory elements (24) . We found five perfect half-palindromic estrogen-responsive element (ERE) motifs, but no discernible complete androgen or glucocorticoid-responsive elements (25) . Given the availability of a highly sensitive, hormonally dependent, and estrogen receptor-mediated transactivation assay of ERE enhancer activity (26), we undertook to examine the possible estrogenic enhancement of hCRH 5' flanking region-regulated chloramphenicol acetyltransferase (CAT) reporter constructs and to compare its effect to that of Xenopus vitellogenin A2 gene enhancer (27). We also tested the ability of a synthetic peptide spanning the DNA binding domain of the human estrogen receptor, to bind specifically to the two perfect half-palindromic ERE sequences proximal to the transcription start site ofthe hCRH gene, using gel retardation and immunoprecipitation assays.
Methods

Materials
Restriction enzymes and lipofectin were obtained from Bethesda Research Laboratories (Gaithersburg, MD); cell culture products from Biofluids Inc. (Rockville, MD); activated charcoal, 1 
Methods
Preparation ofphCRHO.9CAT (hCRH construct 1) and phCRH2.4CAT (hCRH construct 2) constructs. The derivation of these constructs is shown in Fig. 1 . The 88 l-bp-long Sall to HindIII hCRH DNA fragment (phCRH0.9) was enzymatically removed from a 3.8-kb HindIII fragment including the hCRH gene that had been subcloned in a Bluescript vector (23), purified after agarose gel electrophoresis by the geneclean method, and quantified as previously described (31 Cell culture and DNA transfection. Cells were maintained in 90% DME supplemented with 10% charcoal-treated FCS (31) , glutamine (286 mg/liter), penicillin (100 ug/ml), streptomycin (100 jg/ml), and kanamycin (50 ,g/ml). They were cultured in 6-mm petri dishes at 37°C under 95% 02-5% CO2 until 70% confluent, and washed with DME before transfection with DNA-lipofectin complex, prepared as described by the supplier. The DNAs transfected were phCRHO.9CAT (15 ,ug) Assayfor CATactivity. CAT activity was determined as previously described (32). Quantitation of the conversion achieved was performed in a betascope radioactive counting device (Betascope 603 blot analyzer, Betagen Co., Waltham, MA). The degree of acetylation depended linearly on the amount of added protein. Assay for ,B-galactosidase was done as previously described (33) .
Gel retardation. Complex formation between SERP and the various test oligomeric DNAs was first assessed by gel retardation. The binding reaction was started by adding 1 MlI (about 0.5 pmol) of the appropriate 32P-3'-end-labeled synthetic oligonucleotide to 9 Ml ofbinding assay buffer containing 5 MAg of SERP and 1 Mg of poly(dIdC), as previously described (34) , and allowed to proceed at room temperature for 30 min. Samples were then run on a 8% polyacrylamide gel (30:1 acrylamide to bisacrylamide) that had been pre-electrophoresed at 30 mA in high salt buffer (35) at room temperature.
Immunoprecipitation. Complex formation between SERP and the various test oligomeric DNAs was also assessed by immunoprecipitation with a mouse anti-hER monoclonal antibody followed by a 12% SDS-PAGE. Complexes prepared with or without SERP, as described above, were further incubated at 4°C overnight, after addition of 10 MA of anti-hER antibody. At that time, 250 Ml of PBS containing 0.05% Tween-20 and 50 Ml of a suspension of magnetic beads coated with sheep anti-mouse IgG (Dynabeads M-450), were added. The tubes were then rotated at 4°C for 30 min and the precipitates were washed five times with 500 M1 of PBS containing 0.05% Tween-20. The complexes were then eluted from the beads by heating to 950C in 100 Ml of SDS sample buffer and analyzed on a 12% SDS-polyacrylamide gel, as previously described (36) .
Results
Two hCRH 5' flanking region-driven CAT constructs were prepared and transiently expressed in CV-1 cells, supplemented with a cotransfected ER cDNA expression plasmid. Fig. 2 shows that the transfection assay employed depended directly on the presence of all the components of the estrogen transduction pathway examined, including a functional EREcontaining CAT construct, functional ER, and its ligand. Thus, CAT activity in the absence of added functional ER was minimal and independent of the hormone (lanes I and 2), and hormonally dependent CAT activity was mediated by exogenously added ER, since endogenous cellular ER levels were not sufficient to elicit a CAT effect (lanes 3 and 4). Table I summarizes the results of hCRH ERE activity expressed relative to that ofXenopus vitellogenin A2 enhancer. Construct 2, having four perfect half-palindromic EREs, gave a more potent estrogenic effect than construct 1, which had only two of these elements. These effects, were 10-20% of that obtained with the Xenopus vitellogenin CAT construct. The three different CAT constructs, had comparable baseline activity in transfections with A(ER)cDNA, in the presence or absence of E2, and with ERcDNA, in the absence of estradiol.
The stimulation of transcription of the two hCRH promoter-driven CAT constructs by E2 indicated that the ER may bind to the perfect half-palindromic ERE sequences present in the promoter region of the hCRH gene. Analogous binding of the ER has been demonstrated in the ovalbumin gene (34) . To test this hypothesis, we synthesized 35-mer oligonucleotides containing the two perfect half-palindromic EREs present in common in both hCRH constructs examined (hCRH-l, hCRH-2), a perfect ERE, a mutated half-palindromic ERE (hCRH-2 Mut), and a fragment lacking an ERE but containing a TRE consensus (Fig. 3 A) , and examined their ability to bind to a 79-amino acid synthetic peptide spanning the DNA binding domain of the human ER (SERP) (Fig. 3 B) . Gel retardation analysis revealed characteristic complexes migrating as double bands between SERP and either perfect ERE, hCRH-l, or hCRH-2 ( Fig. 3 C, lanes 1-3) , but not between SERP and hCRH-2 Mut or TRE (Fig. 3 C, lanes 4 and 5) . Immunoprecipitation analysis revealed, as expected, no im- (43) . The estrogenic enhancement observed was weak compared to that observed with the Xenopus vitellogenin A2 enhancer. It was, however, specific and reproducible. This regulatory property of the human gene may explain the high level of CRH expression seen in the human placenta (44) and is further supported by our observation of hCRH gene expression in the estrogen receptor positive human breast cell line MCF-7 (N. C. Vamvakopoulos, unpublished observations) and rat and human ovaries (45) . hCRH gene expression is stimulated by glucocorticoids in the placenta (46) , and the mechanism of this is unclear, in light of the lack of a discernible complete glucocorticoid responsive element in the 3625-bp 5' flanking the gene. Synergism ofestrogens and glucocorticoids, however, has been noted in the chicken ovalbumin gene (47), suggestive of some interaction between the two pathways, which might explain this phenomenon.
Estrogen receptors are widely distributed in the brain, including the limbic system and the hypothalamus (48) . Our findings implicate the CRH gene and, therefore, the HPA axis, as a potentially important target of ovarian steroids and a potential mediator of gender related differences in the stress response and HPA axis activity. Data obtained in rats, demonstrating that chronic estradiol treatment ofovariectomized animals stimulates paraventricular nucleus (PVN) CRH mRNA levels (49) and increases ACTH and corticosterone secretion basally and in response to stress (50) , and the demonstration of elevated PVN CRH mRNA in the afternoon of proestrous, at the approximate time of the estrogen-induced preovulatory surge ofluteinizing hormone (5 1 ), support this concept. These effects of estrogens on the CRH neuron suggest that the hypothalamic-pituitary-gonadal (HPG) axis, which is known to be inhibited by hormones of the HPA axis at the hypothalamic, pituitary, gonadal, and sex steroid target tissue levels during stress ( 14, 15) , appears to be also influencing the latter in a positive fashion, by slightly enhancing CRH gene transcription. Thus, these data support a mutual, bidirectional interaction between the HPG and HPA axes. In addition to explaining the slightly increased, basal and stress-stimulated HPA axis function in the female gender, the estrogen-induced enhancement ofthe CRH neuron may also help explain the paradox of negative estrogen feedback effect on the hypothalamic gonadotropin-releasing hormone (GnRH) neuron (52) , which, unlike the PVN, lacks estrogen receptors (53) . The negative estrogen feedback might, thus, be exerted indirectly, via a subgroup of CRH neurons. CRH has been reported to suppress GnRH secretion through a direct and an indirect, arcuate nucleus proopiomelanocortin/13-endorphin-mediated path ( 15, 54) .
The immune/inflammatory reaction is greater in female than in male animals and humans, and in keeping with this, autoimmune inflammatory disease has significantly higher prevalence in the female than the male sex of several species (55 A.
B.
mune inflammatory disease, in which we have demonstrated also decreased hypothalamic CRH secretion and, hence, diminished glucocorticoid production and defective suppression of inflammation (56-58). Although the decreased production of CNS CRH and increased secretion of immune CRH are associated with the high susceptibility ofthis animal to autoimmune inflammatory disease in both sexes, both the susceptibility and the actual inflammatory responses, including expression of immune CRH in peripheral inflammatory sites, are greater in the female than the male (59, 60) . Estrogen-mediated enhancement of immune CRH secretion might be an explanation for this sexual dimorphism in the Lewis rat, as well as, albeit to a lesser extent, in other rat strains or animal species (61) . These findings suggest that homeostatic regulation involves complex mutual interactions between the reproductive axis, HPA axis and the immune system, in which estrogens and CRH may be playing central roles. Certainly, other molecules involved in the regulation of these axes, such as several neurotransmitters, cytokines, and lipid mediators, may also participate in the above interactions and may contribute to their sexual dimorphism.
